Background

Adamantyl-substituted retinoid related molecules are a unique class of compounds which have been found to induce apoptosis, or cell death, in many different tumor types. Currently, there is an unmet medical need for cancer treatments that display enhanced pharmacologic properties such as bioavailability, increased solubility or less toxicity, particularly for cancers such as leukemias. The current invention provides apoptosis inducing compounds for the treatment of various cancer types, including leukemias.

Lead Inventor

Marcia Dawson, Ph.D.

Dawson lab homepage

Selected References
List of references via Pubmed

Patent Information

Full title: Therapeutic Compounds

Patent/Application #: 61/289,977

Priority date: 2-23-2009

Foreign filing: tbd

Burnham ID: 10-001

Status

Available for licensing